Mereo BioPharma Group plc
MREO
$1.74
$0.042.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.00% | -- | -- | -88.89% | -88.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.00% | -- | -- | -88.89% | -88.89% |
| Cost of Revenue | 125.98% | -- | -- | -110.98% | -121.66% |
| Gross Profit | -75.60% | -- | -- | -80.45% | -77.34% |
| SG&A Expenses | 10.16% | 55.46% | 43.46% | 4.52% | -7.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.97% | 32.71% | 23.10% | -7.64% | -18.11% |
| Operating Income | -17.71% | -84.45% | -68.46% | -14.32% | 1.57% |
| Income Before Tax | -32.56% | -75.59% | -44.18% | -53.63% | -10.92% |
| Income Tax Expenses | -- | -- | -- | -734.84% | -496.13% |
| Earnings from Continuing Operations | -34.48% | -79.14% | -46.78% | -51.43% | -8.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.48% | -79.14% | -46.78% | -51.43% | -8.91% |
| EBIT | -17.71% | -84.45% | -68.46% | -14.32% | 1.57% |
| EBITDA | -17.96% | -86.64% | -69.86% | -14.07% | 2.30% |
| EPS Basic | -20.43% | -63.27% | -31.05% | -32.81% | 3.17% |
| Normalized Basic EPS | -18.67% | -60.00% | -28.78% | -34.86% | 1.36% |
| EPS Diluted | -20.43% | -63.27% | -31.05% | -28.50% | 8.34% |
| Normalized Diluted EPS | -18.67% | -60.00% | -28.78% | -34.86% | 1.36% |
| Average Basic Shares Outstanding | 11.87% | 12.08% | 12.14% | 12.59% | 11.99% |
| Average Diluted Shares Outstanding | 11.87% | 12.08% | 12.14% | 12.59% | 11.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |